Peptide YY and glucagon-like peptide-1 contribute to decreased food intake after Roux-en-Y gastric bypass surgery

[1]  J. Holst,et al.  In vivo and in vitro degradation of peptide YY3-36 to inactive peptide YY3-34 in humans. , 2016, American journal of physiology. Regulatory, integrative and comparative physiology.

[2]  J. Holst,et al.  Effects of endogenous GLP-1 and GIP on glucose tolerance after Roux-en-Y gastric bypass surgery. , 2016, American journal of physiology. Endocrinology and metabolism.

[3]  J. Holst,et al.  Oxyntomodulin Identified as a Marker of Type 2 Diabetes and Gastric Bypass Surgery by Mass-spectrometry Based Profiling of Human Plasma , 2016, EBioMedicine.

[4]  A. Astrup,et al.  Effects of RYGB on energy expenditure, appetite and glycaemic control: a randomized controlled clinical trial , 2016, International Journal of Obesity.

[5]  J. Holst,et al.  Heterogeneity of glucagonomas due to differential processing of proglucagon-derived peptides , 2015, Endocrinology, diabetes & metabolism case reports.

[6]  A. Lacy,et al.  Gastrointestinal Hormones and Weight Loss Maintenance Following Roux-en-Y Gastric Bypass. , 2015, The Journal of clinical endocrinology and metabolism.

[7]  R. DeFronzo,et al.  Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial. , 2015, JAMA.

[8]  C. L. le Roux,et al.  Roux-en-Y Gastric Bypass Surgery Increases Respiratory Quotient and Energy Expenditure during Food Intake , 2015, PloS one.

[9]  J. Holst,et al.  Improvements in glucose metabolism early after gastric bypass surgery are not explained by increases in total bile acids and fibroblast growth factor 19 concentrations. , 2015, The Journal of clinical endocrinology and metabolism.

[10]  J. Holst,et al.  Stability of glucagon-like peptide 1 and glucagon in human plasma , 2015, Endocrine connections.

[11]  C. Roth,et al.  Initial evidence that GLP-1 receptor blockade fails to suppress postprandial satiety or promote food intake in humans , 2014, Appetite.

[12]  C. Beglinger,et al.  Effect of glucagon-like peptide-1 receptor antagonism on appetite and food intake in healthy men. , 2014, The American journal of clinical nutrition.

[13]  A. Astrup,et al.  Effects of PYY3-36 and GLP-1 on energy intake, energy expenditure, and appetite in overweight men. , 2014, American journal of physiology. Endocrinology and metabolism.

[14]  J. Holst,et al.  Early Enhancements of Hepatic and Later of Peripheral Insulin Sensitivity Combined With Increased Postprandial Insulin Secretion Contribute to Improved Glycemic Control After Roux-en-Y Gastric Bypass , 2014, Diabetes.

[15]  J. Holst,et al.  Mechanisms of changes in glucose metabolism and bodyweight after bariatric surgery. , 2014, The lancet. Diabetes & endocrinology.

[16]  J. Holst,et al.  Exaggerated Glucagon-Like Peptide 1 Response Is Important for Improved β-Cell Function and Glucose Tolerance After Roux-en-Y Gastric Bypass in Patients With Type 2 Diabetes , 2013, Diabetes.

[17]  J. Holst,et al.  The effect of exogenous GLP-1 on food intake is lost in male truncally vagotomized subjects with pyloroplasty. , 2013, American Journal of Physiology - Gastrointestinal and Liver Physiology.

[18]  S. Madsbad,et al.  Fast pouch emptying, delayed small intestinal transit, and exaggerated gut hormone responses after Roux‐en‐Y gastric bypass , 2013, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[19]  J. Holst,et al.  Gut hormones, early dumping and resting energy expenditure in patients with good and poor weight loss response after Roux-en-Y gastric bypass , 2013, International Journal of Obesity.

[20]  J. Holst,et al.  Acute and long-term effects of Roux-en-Y gastric bypass on glucose metabolism in subjects with Type 2 diabetes and normal glucose tolerance. , 2012, American journal of physiology. Endocrinology and metabolism.

[21]  J. Holst,et al.  Changes in Gastrointestinal Hormone Responses, Insulin Sensitivity, and Beta-Cell Function Within 2 Weeks After Gastric Bypass in Non-diabetic Subjects , 2012, Obesity Surgery.

[22]  C. Bouchard,et al.  Bariatric surgery and long-term cardiovascular events. , 2012, JAMA.

[23]  P. Matthews,et al.  The Gut Hormones PYY3-36 and GLP-17-36 amide Reduce Food Intake and Modulate Brain Activity in Appetite Centers in Humans , 2011, Cell metabolism.

[24]  J. Holst,et al.  Changes in glucose homeostasis after Roux-en-Y gastric bypass surgery for obesity at day three, two months, and one year after surgery: role of gut peptides. , 2011, The Journal of clinical endocrinology and metabolism.

[25]  Elizabeth A. Odstrcil,et al.  The contribution of malabsorption to the reduction in net energy absorption after long-limb Roux-en-Y gastric bypass. , 2010, The American journal of clinical nutrition.

[26]  J. Holst,et al.  Twelve weeks treatment with the DPP‐4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non‐glucose induced insulin secretion in patients with type 2 diabetes mellitus , 2010, Diabetes, obesity & metabolism.

[27]  S. Bloom,et al.  Gut Hormones as Mediators of Appetite and Weight Loss After Roux-en-Y Gastric Bypass , 2007, Annals of surgery.

[28]  Mohammad A Ghatei,et al.  Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively. , 2005, Endocrinology.

[29]  Rachel L. Batterham,et al.  Gut hormone PYY3-36 physiologically inhibits food intake , 2002, Nature.

[30]  A. Astrup,et al.  A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. , 2001, The Journal of clinical endocrinology and metabolism.

[31]  P. Mannon,et al.  Primary structures of PYY, [Pro(34)]PYY, and PYY-(3-36) confer different conformations and receptor selectivity. , 2000, American journal of physiology. Gastrointestinal and liver physiology.

[32]  J. Rehfeld.  Accurate measurement of cholecystokinin in plasma. , 1998, Clinical chemistry.

[33]  A. Turner,et al.  Processing and metabolism of peptide-YY: pivotal roles of dipeptidylpeptidase-IV, aminopeptidase-P, and endopeptidase-24.11. , 1994, Endocrinology.

[34]  J. Holst,et al.  Tissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans , 1994, Diabetes.

[35]  S. Bloom,et al.  Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39. , 1999, Diabetes.

[36]  A. Harris,et al.  Somatostatin and somatostatin analogues: pharmacokinetics and pharmacodynamic effects. , 1994, Gut.